Non-invasive programmed stimulation to identify high-risk patients with implanted cardioverter defibrillator (the NIPS-ICD study): study protocol for a randomized controlled trial

Piotr Futyma, Marian Futyma, Piotr Kułakowski, Piotr Futyma, Marian Futyma, Piotr Kułakowski

Abstract

Background: The use of an implantable cardioverter defibrillator (ICD) is a widely used and effective therapy, which reduces the risk of cardiac death in many cardiac diseases, both implanted for secondary and primary prevention. However, recurrent arrhythmias and ICD discharges have adverse prognostic significance. Additional parameters that would identify patients who are at increased risk of arrhythmias and appropriate ICD interventions would be of clinical value. Modern ICDs are relatively complex devices with a number of functions, including the possibility to perform noninvasive programmed stimulation (NIPS) with an implanted electrode located in the right ventricle.

Methods/design: The aim of the study is to evaluate the usefulness of NIPS in determining the likelihood of life-threatening arrhythmic events in patients with ICD. The study will include 150 consecutive patients with an ICD implanted both for primary and secondary prevention, regardless of etiology, who are followed in the outpatient clinic of our center and do not meet the exclusion criteria. A 12-step St. George's Hospital NIPS protocol using ICD will be performed. The endpoint is to induce sustained ventricular arrhythmia (VT lasting more than 30 seconds or hemodynamically unstable VT/VF) or the end of the protocol. In case of serious and/or hemodynamically unstable heart rhythm disorders resistant to treatment with a low-energy antiarrhythmic pacing (ATP), the patient receives a short-term intravenous general anesthesia, and internal or external defibrillation is performed. Outpatient follow-up will be conducted during the pre-scheduled ICD control visits. An analysis of records of a registered memory device will be collected, a patient will be interviewed, and physical examination will be carried out. The follow-ups will be held every 3 months for 1 year. The primary endpoint of the follow-up will be appropriate intervention of ICD or sudden cardiac (arrhythmic) death; the secondary, appropriate ICD intervention, or death from cardiovascular causes; and the tertiary, appropriate ICD intervention, death or hospitalization for cardiovascular causes.

Discussion: It is expected that appropriate ICD interventions during follow-up will occur more often in patients who had sustained ventricular arrhythmias induced during NIPS.

Clinical trials registry: ClinicalTrials.gov, NCT02373306 , date of registration: 26 February 2015.

References

    1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40. doi: 10.1056/NEJM199612263352601.
    1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83. doi: 10.1056/NEJMoa013474.
    1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006; 8:746–837.
    1. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008;52:1111–21. doi: 10.1016/j.jacc.2008.05.058.
    1. Lee DS, Tu JV, Austin PC, Dorian P, Yee R, Chong A, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol. 2007;49:2408–15. doi: 10.1016/j.jacc.2007.02.058.
    1. Borne RT, Varosy PD, Masoudi FA. Implantable cardioverter defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med. 2013;1:1–7.
    1. Bigger JT., Jr Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569–75. doi: 10.1056/NEJM199711273372201.
    1. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8. doi: 10.1056/NEJMoa041489.
    1. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90. doi: 10.1056/NEJM199912163412503.
    1. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874–9. doi: 10.1001/jama.292.23.2874.
    1. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–36. doi: 10.1056/NEJMoa0901889.
    1. van Rees JB, Borleffs CJW, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter defibrillator shocks Incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57:556–62. doi: 10.1016/j.jacc.2010.06.059.
    1. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–17. doi: 10.1056/NEJMoa071098.
    1. Abello M, Merino JL, Peinado R, Gnoatto M, Arias MA, Gonzalez-Vasserot M, et al. Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia. Eur Heart J. 2006;27:89–95. doi: 10.1093/eurheartj/ehi500.
    1. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of a cardioverter defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–96. doi: 10.1016/j.jacc.2007.08.058.
    1. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter defibrillator. J Am Coll Cardiol. 2012;59:2075–9. doi: 10.1016/j.jacc.2012.02.036.
    1. Tung R, Josephson ME, Reddy V, Reynolds MR. SMASH-VT Investigators. Influence of clinical and procedural predictors on ventricular tachycardia ablation outcomes: an analysis from the substrate mapping and ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial (SMASH-VT) J Cardiovasc Electrophysiol. 2010;21:799–803.
    1. Hayashi T, Fukamizu S, Hojo R, Komiyama K, Tanabe Y, Tejima T, et al. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention. Europace. 2013;15:1507–15. doi: 10.1093/europace/eut050.
    1. Dagres N, Cantù F, Geelen P, Lewalter T, Proclemer A, Blomström-Lundqvist C. Current practice of ventricular tachycardia ablation in patients with implantable cardioverter defibrillator s. Europace. 2012;14:135–7. doi: 10.1093/europace/eur411.
    1. Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, Greenspan AM. Recurrent sustained ventricular tachycardia 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens. Circulation. 1978;58:986–97. doi: 10.1161/01.CIR.58.6.986.
    1. Behr ER, Elliott P, McKenna WJ. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev. 2002;6:482–6. doi: 10.1023/A:1021161114347.
    1. Kleiman RB, Callans DJ, Hook BG, Marchlinski FE. Effectiveness of noninvasive programmed stimulation for initiating ventricular tachyarrhythmias in patients with third-generation implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 1994;17:1462–8. doi: 10.1111/j.1540-8159.1994.tb01510.x.
    1. Frankel DS, Mountantonakis SE, Zado ES, Anter E, Bala R, Cooper JM, et al. Noninvasive programmed ventricular stimulation early after ventricular tachycardia ablation to predict risk of late recurrence. J Am Coll Cardiol. 2012;59:1529–35. doi: 10.1016/j.jacc.2012.01.026.
    1. Bhavnani SP, Kluger J, Coleman CI, White CM, Guertin D, Shafi NA, et al. The prognostic impact of shocks for clinical and induced arrhythmias on morbidity and mortality among patients with implantable cardioverter defibrillator s. Heart Rhythm. 2010;7:755–60. doi: 10.1016/j.hrthm.2010.02.039.
    1. Costeas XF, Link MS, Foote CB, Homoud MK, Wang PJ, Estes NA. Predictors of ventricular tachycardia recurrence in 100 patients receiving tiered therapy defibrillators. Clin Cardiol. 2000;23:852–6. doi: 10.1002/clc.4960231113.
    1. Daubert JP, Winters SL, Subacius H, Berger RD, Ellenbogen KA, Taylor SG, et al. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009;32:755–61. doi: 10.1111/j.1540-8159.2009.02362.x.
    1. Zehender M, Brugada P, Geibel A, Waldecker B, Stevenson W, Wellens HJ. Programmed electrical stimulation in healed myocardial infarction using a standardized ventricular stimulation protocol. Am J Cardiol. 1987;59:578–85. doi: 10.1016/0002-9149(87)91173-8.
    1. Kulakowski P, Bashir Y, Heald S, Paul V, Anderson MH, Gibson S, et al. Effects of procainamide on the signal-averaged electrocardiogram in relation to the results of programmed ventricular stimulation in patients with sustained monomorphic ventricular tachycardia. J Am Coll Cardiol. 1993;21:1428–39. doi: 10.1016/0735-1097(93)90320-Z.
    1. Kuller L, Lilienfeld A, Fisher R. An epidemiological study of sudden and unexpected deaths in adults. Medicine (Baltimore). 1967; 46:341–61.
    1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. doi: 10.1056/NEJMoa043399.
    1. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter defibrillator therapies: Is device therapy proarrhythmic? Am J Cardiol. 2006;97:1255–61. doi: 10.1016/j.amjcard.2005.11.048.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera